Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.665957
Title: Aspects of functional constipation : a trial of an opioid antagonist as a treatment and an investigation of the colonic microbiota associated with the illness
Author: Bignell, Mark
ISNI:       0000 0004 5352 481X
Awarding Body: University of East Anglia
Current Institution: University of East Anglia
Date of Award: 2014
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
INTRODUCTION Functional constipation (FC) is a common condition which affects patients’ quality of life (QoL), is of uncertain pathophysiology, and is poorly treated. The aims of this research were to conduct a randomised, placebo-controlled trial investigating an opiate antagonist (Naloxone - Nalcol™) on symptom relief in FC and secondly to describe the colonic microbiota in FC and determine the effect of Nalcol™ on it. MATERIAL AND METHODS The trial consisted of; a 2 week screening period (Period I), a 4 week trial period of Nalcol™ vs. Placebo (Period II), and a 4 week open label period with all patients taking Nalcol™ (Period III). The primary outcome was patients’ assessment of ‘satisfactory improvement in the preceding 2 weeks’ after each period. The secondary outcomes were: changes in QoL, stool type and frequency, and transit time. A subset of patients donated stool samples at the end of each period for microbiological analysis which were compared with controls without FC. Faecal samples were analysed using denaturing gradient gel electrophoresis (DGGE), fluorescence in situ hybridisation (FISH), and pyrosequencing. RESULTS 41 females were recruited (median age 45, range 23-76 years) .There were no significant differences in ‘satisfactory improvement in the preceding 2 weeks’, (Nalcol™ vs. Placebo, 20% vs. 24%, p=1.00, n=41) or any secondary outcomes. Nalcol™ use was associated with more bloating (40% vs. 5%, p=0.009). Patients with FC had significant reductions in the Firmicutes phylum (25% vs. 45%, p=0.004) and Bifidiobacteria spp. (0.67 vs. 0.88 log10 cell/g, p=0.03), with increases in the Bacteroidetes phylum (66% vs. 41%, p=0.002) compared to controls. CONCLUSION Nalcol™ had no clinical benefits for managing FC in this trial and cannot be recommended in this group of patients. Differences in the colonic microbiota in FC warrant further investigation to see how it is implicated in the pathophysiology of FC.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.665957  DOI: Not available
Share: